HWAIL PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,585 KRW | -0.31% |
|
-0.31% | -28.12% |
| Sales 2015 | 106B 77.16M | Sales 2016 | 112B 81.07M | Capitalization | 110B 79.73M |
|---|---|---|---|---|---|
| Net income 2015 | 5.45B 3.96M | Net income 2016 | 6.38B 4.64M | EV / Sales 2015 | 1.01 x |
| Net Debt 2015 | 20.17B 14.66M | Net Debt 2016 | 5.05B 3.67M | EV / Sales 2016 | 1.03 x |
| P/E ratio 2015 |
16
x | P/E ratio 2016 |
17.2
x | Employees | 130 |
| Yield 2015 |
2.32% | Yield 2016 |
1.85% | Free-Float | 56.28% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.31% | ||
| 1 week | -0.31% | ||
| Current month | -4.06% | ||
| 1 month | -9.01% | ||
| 3 months | -20.67% | ||
| 6 months | -21.53% | ||
| Current year | -28.12% |
1 week
1 571.00
1 611.00
1 month
1 551.001 720.00
Current year
1 550.002 265.00
1 year
1 550.002 410.00
3 years
1 550.005 080.00
5 years
1 303.335 933.33
10 years
1 303.335 933.33
| Managers | Title | Age | Since |
|---|---|---|---|
Pil-Jun Park
CEO | Chief Executive Officer | 63 | 79-04-30 |
Joong-Myung Cho
CEO | Chief Executive Officer | 75 | 13-09-30 |
Yong-Ho Jung
CTO | Chief Tech/Sci/R&D Officer | 72 | 10-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Joong-Myung Cho
CEO | Chief Executive Officer | 75 | 13-09-30 |
Pil-Jun Park
CEO | Chief Executive Officer | 63 | 79-04-30 |
Sang-Chun Ahn
BRD | Director/Board Member | 61 | 13-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 1,585 | -0.31% | 54,187 |
| 24-04-24 | 1,590 | -0.69% | 79,314 |
| 24-04-23 | 1,601 | +0.06% | 47,508 |
| 24-04-22 | 1,600 | +0.88% | 72,244 |
| 24-04-19 | 1,586 | -0.25% | 70,138 |
End-of-day quote Korea S.E., April 24, 2024
More quotes
HWAIL PHARMACEUTICAL CO., LTD. is a Korea-based company mainly engaged in the manufacture and distribution of pharmaceutical raw materials. The Company produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. It also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -28.12% | 75.03M | |
| +24.71% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.28% | 233B | |
| +5.49% | 201B | |
| -10.06% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- A061250 Stock
